Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

(2020) Yingming Li et al.   CLINICAL CANCER RESEARCH

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer

(2020) Himisha Beltran et al.   JOURNAL OF CLINICAL INVESTIGATION

The DNA methylation landscape of advanced prostate cancer

(2020) Shuang G. Zhao et al.   NATURE GENETICS

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

(2019) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Whole Genome and Transcriptional Analysis of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Demonstrates Intra-Class Heterogeneity

(2019) Rahul R. Aggarwal et al.   MOLECULAR CANCER RESEARCH

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

(2019) Andrew J. Armstrong et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

(2019) Mark P. Labrecque et al.   JOURNAL OF CLINICAL INVESTIGATION

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

(2018) David A. Quigley et al.   CELL

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

(2018) Srinivas R. Viswanathan et al.   CELL

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

(2018) Jonathan Welti et al.   CLINICAL CANCER RESEARCH

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting

(2018) Jun Luo et al.   EUROPEAN UROLOGY

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer

(2018) Diogo A. Bastos et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

(2018) Rahul Aggarwal et al.   JOURNAL OF CLINICAL ONCOLOGY

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

(2018) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

(2018) Matti Annala et al.   Cancer Discovery

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

(2018) A J Armstrong et al.   ANNALS OF ONCOLOGY

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer

(2018) Rana R. McKay et al.   CANCER

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer

(2017) Howard I. Scher et al.   EUROPEAN UROLOGY

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

(2017) Tomasz M. Beer et al.   EUROPEAN UROLOGY

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

(2017) Rahul Aggarwal et al.   Journal of the National Comprehensive Cancer Network

Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation

(2016) Jamie M. Sperger et al.   CLINICAL CANCER RESEARCH

Prostate Cancer, Version 1.2016

(2016) James L. Mohler et al.   Journal of the National Comprehensive Cancer Network

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

(2016) I. A. Asangani et al.   MOLECULAR CANCER RESEARCH

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting

(2016) E S Antonarakis et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

(2016) Christine Henzler et al.   Nature Communications

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

(2016) Howard I. Scher et al.   JAMA Oncology

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer

(2015) H. Beltran et al.   CLINICAL CANCER RESEARCH

Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer

(2015) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

New Treatment Options in Castration-Resistant Prostate Cancer

(2015) Andrew J. Armstrong   Journal of the National Comprehensive Cancer Network

Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer

(2014) Z. Yu et al.   CLINICAL CANCER RESEARCH

Aggressive Variants of Castration-Resistant Prostate Cancer

(2014) H. Beltran et al.   CLINICAL CANCER RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective Nucleic Acid Removal via Exclusion (SNARE): Capturing mRNA and DNA from a Single Sample

(2013) Lindsay Strotman et al.   ANALYTICAL CHEMISTRY

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

(2013) Vivek K. Arora et al.   CELL

An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

(2013) M. Korpal et al.   Cancer Discovery

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

(2013) J. D. Joseph et al.   Cancer Discovery

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression

(2011) Y. Li et al.   CANCER RESEARCH

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

(2009) Howard I Scher et al.   LANCET ONCOLOGY

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

(2008) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS